Malignant Anal Neoplasm — Trials

Malignant Anal Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 68
Recruiting: 34
Ph III recruiting: 2
Growth YoY: —
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 27.1%
Trials / 1,000 deaths: 42.5 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (22)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07692152	Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma	recruiting	Phase 3	350	Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER	1	Jul 9, 2026	clinicaltrials
NCT06207981	Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA(KANALRAD)	recruiting	Phase 3	310	Federation Francophone de Cancerologie Digestive